Olufunmilayo Olopade, M.D.
Professor of Medicine
Director, Hematology/Oncology Fellowship Program
Director, Center for Clinical Cancer Genetics
M.D., University of Ibadan

Research Description

My research interests are diverse and include: treatment of breast cancer, especially in young or pregnant women; familial cancers; molecular genetics of cancer; cancer risk assessment and chemoprevention; breast cancer and minority populations and disparities in health outcomes. My clinical interests include breast cancer, cancer risk assessment, cancer prevention, and general hematology and medical oncology.

Selected Publications

Pilot study demonstrating potential association between breast cancer image-based risk phenotypes and genomic biomarkers.
Li H, Giger ML, Sun C, Ponsukcharoen U, Huo D, Lan L, Olopade OI, Jamieson AR, Brown JB, Rienzo AD
(2014 Mar) Med Phys. 2014 Mar;41(3):031917. doi: 10.1118/1.4865811. 24593735

Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis.
Harrell JC, Pfefferle AD, Zalles N, Prat A, Fan C, Khramtsov A, Olopade OI, Troester MA, Dudley AC, Perou CM
(2014 Jan) Clin Exp Metastasis. 2014 Jan;31(1):33-45. doi: 10.1007/s10585-013-9607-4. Epub 2013 Aug 22. 23975155 ( Full Text )

Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution.
Oluwasola AO, Malaka D, Khramtsov AI, Ikpatt OF, Odetunde A, Adeyanju OO, Sveen WE, Falusi AG, Huo D, Olopade OI
(2013 Dec) Ann Diagn Pathol. 2013 Dec;17(6):526-30. doi: 10.1016/j.anndiagpath.2013.07.003. Epub 2013 Oct 2. 24095629

International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers.
Semple J, Metcalfe KA, Lynch HT, Kim-Sing C, Senter L, Pal T, Ainsworth P, Lubinski J, Tung N, Eng C, Gilchrist D, Blum J, Neuhausen SL, Singer CF, Ghadirian P, Sun P, Narod SA
(2013 Nov) Ann Surg Oncol. 2013 Nov;20(12):3817-22. doi: 10.1245/s10434-013-3040-4. Epub 2013 Jun 6. 23740344

The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation.
Valentini A, Lubinski J, Byrski T, Ghadirian P, Moller P, Lynch HT, Ainsworth P, Neuhausen SL, Weitzel J, Singer CF, Olopade OI, Saal H, Lyonnet DS, Foulkes WD, Kim-Sing C, Manoukian S, Zakalik D, Armel S, Senter L, Eng C, Grunfeld E, Chiarelli AM, Poll A, Sun P, Narod SA
(2013 Nov) Breast Cancer Res Treat. 2013 Nov;142(1):177-85. doi: 10.1007/s10549-013-2729-1. Epub 2013 Oct 18. 24136669 ( Full Text )

Breast cancer detected on an incident (second or subsequent) round of screening MRI: MRI features of false-negative cases.
Yamaguchi K, Schacht D, Newstead GM, Bradbury AR, Verp MS, Olopade OI, Abe H
(2013 Nov) AJR Am J Roentgenol. 2013 Nov;201(5):1155-63. doi: 10.2214/AJR.12.9707. 24147491

Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study.
Arowolo OA, Njiaju UO, Ogundiran TO, Abidoye O, Lawal OO, Obajimi M, Adetiloye AV, Im HK, Akinkuolie AA, Oluwasola A, Adelusola K, Kayode AA, Agbakwuru AE, Oduntan H, Babalola CP, Fleming G, Olopade OC, Falusi AG, Durosinmi MA, Olopade OI
(2013 Sep) Breast J. 2013 Sep-Oct;19(5):470-7. doi: 10.1111/tbj.12149. Epub 2013 Jul 19. 23865786

Risk factors for pregnancy-associated breast cancer: a report from the Nigerian Breast Cancer Study.
Hou N, Ogundiran T, Ojengbede O, Morhason-Bello I, Zheng Y, Fackenthal J, Adebamowo C, Anetor I, Akinleye S, Olopade OI, Huo D
(2013 Sep) Ann Epidemiol. 2013 Sep;23(9):551-7. doi: 10.1016/j.annepidem.2013.06.008. Epub 2013 Jul 20. 23880155 ( Full Text )

Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density.
Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D
(2013 Sep) J Natl Cancer Inst. 2013 Sep 18;105(18):1365-72. doi: 10.1093/jnci/djt207. Epub 2013 Sep 3. 24003037 ( Full Text )

Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers.
Zheng Y, Ogundiran TO, Falusi AG, Nathanson KL, John EM, Hennis AJ, Ambs S, Domchek SM, Rebbeck TR, Simon MS, Nemesure B, Wu SY, Leske MC, Odetunde A, Niu Q, Zhang J, Afolabi C, Gamazon ER, Cox NJ, Olopade CO, Olopade OI, Huo D
(2013 Jul) Carcinogenesis. 2013 Jul;34(7):1520-8. doi: 10.1093/carcin/bgt090. Epub 2013 Mar 8. 23475944 ( Full Text )

MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.
Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T, Lu J, Park SY, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H
(2013) Nat Commun. 2013;4:1393. doi: 10.1038/ncomms2393. 23340433 ( Full Text )

Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer.
Bhatta SS, Hou N, Moton ZN, Polite BN, Fleming GF, Olopade OI, Huo D, Hong S
(2013) Springerplus. 2013 Jul 30;2:356. doi: 10.1186/2193-1801-2-356. eCollection 2013. 23961419 ( Full Text )

Comprehensive molecular portraits of human breast tumours.
(2012 Oct) Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23. 23000897 ( Full Text )

High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients.
Fackenthal JD, Zhang J, Zhang B, Zheng Y, Hagos F, Burrill DR, Niu Q, Huo D, Sveen WE, Ogundiran T, Adebamowo C, Odetunde A, Falusi AG, Olopade OI
(2012 Sep) Int J Cancer. 2012 Sep 1;131(5):1114-23. doi: 10.1002/ijc.27326. Epub 2012 Jan 27. 22034289

Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution.
Sylvester BE, Huo D, Khramtsov A, Zhang J, Smalling RV, Olugbile S, Polite BN, Olopade OI
(2012 Jan) Clin Cancer Res. 2012 Jan 15;18(2):350-9. doi: 10.1158/1078-0432.CCR-11-1397. Epub 2011 Nov 23. 22114137 ( Full Text )

Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.
Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI
(2009 Sep) J Clin Oncol. 2009 Sep 20;27(27):4515-21. doi: 10.1200/JCO.2008.19.6873. Epub 2009 Aug 24. 19704069 ( Full Text )

BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI
(2005 Dec) Cancer Res. 2005 Dec 1;65(23):10692-9. 16322213

Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI
(2005 Oct) JAMA. 2005 Oct 19;294(15):1925-33. 16234499

MYC is amplified in BRCA1-associated breast cancers.
Grushko TA, Dignam JJ, Das S, Blackwood AM, Perou CM, Ridderstrale KK, Anderson KN, Wei MJ, Adams AJ, Hagos FG, Sveen L, Lynch HT, Weber BL, Olopade OI
(2004 Jan) Clin Cancer Res. 2004 Jan 15;10(2):499-507. 14760071

Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, Sanders MO, Weber BL, Olopade OI
(2002 Mar) Cancer Res. 2002 Mar 1;62(5):1481-8. 11888924